The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19

• Status: Not yet recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to test whether Ivermectin would decrease mortality and reduces chances of getting infected with corona virus, improve management of clinical symptoms and reduce length of stay in ICU and transition probabilities to ICU (ventilator).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre for Infectious Disease Research in Zambia
• Collaborators: Ministry of Health, Zambia; University of Zambia
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

• Individuals diagnosed positive for SARS-CoV-2 by real-time reverse transcription PCR (rRT-PCR with presence of a fever, cough, and/or sore throat.

Exclusion Criteria:

• Patients will be excluded if they report to be allergic to ivermectin or if there is potential for a drug-drug interaction with ivermectin;

• Have chronic illnesses (e.g., ischemic heart disease, heart failure, documented cardiomyopathy, chronic kidney disease, chronic liver disease);

• Have received ivermectin in the last 7 days; are pregnant or lactating;

• Or have participated in any other clinical trial within the last month.